What Astellas Did Right In Using Real-World Evidence For Prograf Approval
Executive Summary
US FDA’s John Concato cites rigorous collection of data and study design in getting Prograf lung transplant indication. Use of real-world evidence in Opdivo trials had mixed results, BMS exec notes.
You may also be interested in...
RWE’s Biggest Role In US FDA Approvals: External Controls For Breakthrough Rare Disease Therapies
Despite broad interest, real-world evidence of efficacy in FDA decisions remains largely limited to orphan diseases and natural history, a Pink Sheet analysis shows.
Keeping Track: Pediatric Approvals, Seres Starts C Diff Submission, And BMS Pulls Reblozyl sBLA Before Possible CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Keeping Track: US FDA Clears Vaxneuvance, Rezurock And Karendia, But Not Teplizumab
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker